BioMarin Pharmaceutical Inc. (BMRN)

NASDAQ: BMRN · IEX Real-Time Price · USD
102.33
-2.06 (-1.97%)
Dec 9, 2022 4:00 PM EST - Market closed
-1.97%
Market Cap 19.40B
Revenue (ttm) 2.01B
Net Income (ttm) 83.91M
Shares Out 185.60M
EPS (ttm) 0.44
PE Ratio 232.57
Forward PE 30.49
Dividend n/a
Ex-Dividend Date n/a
Volume 815,513
Open 104.23
Previous Close 104.39
Day's Range 102.28 - 104.46
52-Week Range 70.73 - 106.72
Beta 0.37
Analysts Buy
Price Target 117.30 (+14.6%)
Earnings Date Oct 26, 2022

About BMRN

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. ... [Read more]

Industry Biotechnology
IPO Date Jul 23, 1999
CEO Jean-Jacques Bienaime
Employees 3,045
Stock Exchange NASDAQ
Ticker Symbol BMRN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 28 analysts, the average rating for BMRN stock is "Buy." The 12-month stock price forecast is 117.3, which is an increase of 14.63% from the latest price.

Price Target
$117.3
(14.63% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Biotech Stock BioMarin Scores Breakout After FDA Announcement

BioMarin broke out after the FDA said it wouldn't hold an advisory committee meeting on its hemophilia A gene therapy. The post Biotech Stock BioMarin Scores Breakout After FDA Announcement appeared fir...

2 weeks ago - Investors Business Daily

Why Is BioMarin (BMRN) Up 14.1% Since Last Earnings Report?

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock?

2 weeks ago - Zacks Investment Research

BioMarin (BMRN) Up After FDA Scraps AdCom Meet for BLA Filing

The FDA decides not to hold an advisory committee meeting for BioMarin Pharmaceuticals' (BMRN) regulatory filing seeking approval for hemophilia A gene therapy, valrox.

2 weeks ago - Zacks Investment Research

Why Biomarin Pharmaceutical Stock Hit A New 52-Week High Today - Biomarin Pharmaceutical (NASDAQ:BMRN)

Biomarin Pharmaceutical Inc (NASDAQ: BMRN) shares are trading higher by 6.97% to $97.54 Wednesday morning after the company announced advancements in the FDA review of ROCTAVIAN for adults with severe h...

2 weeks ago - Benzinga

BioMarin Announces Advancements in FDA Review of ROCTAVIAN™ (Valoctocogene Roxaparvovec) for Adults with Severe Hemop...

FDA No Longer Plans to Hold an Advisory Committee Meeting, as Previously Planned, to Discuss the Biologics License Application (BLA) BioMarin Remains on Track to Host Scheduled Manufacturing Inspections...

2 weeks ago - PRNewsWire

BioMarin Announces Incremental Progress on Biologics License Application (BLA) Review for Valoctocogene Roxaparvovec ...

FDA Pre-Licensure Inspection of Gene Therapy Manufacturing Facility Scheduled FDA Requests Submission of Upcoming 3-Year Data Analysis from Phase 3 GENEr8-1 Study Current PDUFA Target Action Date of Mar...

1 month ago - PRNewsWire

BioMarin to Participate in Two Upcoming Investor Conferences

Credit Suisse 31st Annual Healthcare Conference 2022: November 8th, 8:35amPT/11:35amET, in Rancho Palos Verdes, CA 13th Annual Jefferies Global Healthcare Conference 2022: November 16th, 8:35amGMT, in L...

1 month ago - PRNewsWire

Why BioMarin Pharmaceuticals Fell 6.9% on Thursday

Investors were expecting better top-line numbers from the company's earnings report.

1 month ago - The Motley Fool

BioMarin (BMRN) Q3 Earnings Beat, Sales Miss, Ups Voxzogo View

BioMarin Pharmaceutical's (BMRN) third-quarter 2022 earnings beat estimates, but sales slightly miss the mark.

1 month ago - Zacks Investment Research

BioMarin Pharmaceutical (BMRN) Surpasses Q3 Earnings Estimates

BioMarin (BMRN) delivered earnings and revenue surprises of 21.62% and 1.53%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

BioMarin Announces Third Quarter 2022 Year-over-Year Total Revenue Growth of 24% (31% Excluding KUVAN®)

VOXZOGO® $48 Million Contribution in the Quarter Results in BioMarin Raising Full-year 2022 VOXZOGO Net Product Revenue Guidance to Between $140 Million and $170 Million U.S. Biologics Application for R...

1 month ago - PRNewsWire

Can BioMarin (BMRN) Keep the Earnings Surprise Streak Alive?

BioMarin (BMRN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

1 month ago - Zacks Investment Research

4 Biotech Stocks Set to Outpace Q3 Earnings Estimates

Let us take a look at some biotech stocks, ARGX, BMRN, LLY and GMAB, which are poised to beat on third-quarter earnings.

Other symbols: ARGXGMABLLY
1 month ago - Zacks Investment Research

BioMarin Pharmaceutical CEO on the company's drug pricing strategy

Cramer spoke with BioMarin Pharmaceutical CEO Jean-Jacques Bienaimé on Wednesday.

1 month ago - CNBC Television

BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

BioMarin (BMRN) Hemophilia Gene Therapy BLA Gets FDA Acceptance

If approved, BioMarin's (BMRN) valoctocogene roxaparvovec will become the first gene therapy for treating hemophilia A in the United States. A decision from the FDA is due on Mar 31, 2023.

1 month ago - Zacks Investment Research

FDA Accepts BioMarin's Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults...

If Approved, Would Be 1st Gene Therapy in U.S. for Treatment of Severe Hemophilia A PDUFA Target Action Date is March 31, 2023 SAN RAFAEL, Calif. , Oct. 12, 2022 /PRNewswire/ -- BioMarin Pharmaceutical ...

1 month ago - PRNewsWire

Wall Street Analysts See a 31% Upside in BioMarin (BMRN): Can the Stock Really Move This High?

The mean of analysts' price targets for BioMarin (BMRN) points to a 30.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts ...

1 month ago - Zacks Investment Research

BioMarin (BMRN) Starts Restructuring Moves to Increase Efficiency

BioMarin (BMRN) intends to reduce the existing workforce by nearly 4%. The company plans to use the savings in costs and redirect them toward its operating expenses.

2 months ago - Zacks Investment Research

BioMarin Simplifies Organizational Structure to Increase Efficiency

SAN RAFAEL, Calif. , Oct. 6, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced its decision to redesign the organization to better focus investments that advance its R&D pi...

2 months ago - PRNewsWire

BioMarin to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Wednesday, October 26, at 4:30pm ET

SAN RAFAEL, Calif. , Oct. 4, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a co...

2 months ago - PRNewsWire

BioMarin (BMRN) Refiles BLA With FDA for Hemophilia Gene Therapy

If approved, BioMarin's (BMRN) valoctocogene roxaparvovec will be the first gene therapy for hemophilia A in the United States. The FDA filing also incorporates BMRN's responses to the CRL issued to the...

2 months ago - Zacks Investment Research

BioMarin Resubmits Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Severe Hem...

BLA Includes Substantial Body of Data from Pivotal Phase 3 and Ongoing Phase 1/2 Studies If Approved, Would Be 1st Gene Therapy in U.S. for Treatment of Severe Hemophilia A SAN RAFAEL, Calif. , Sept. 29...

2 months ago - PRNewsWire

Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin

Biotech stocks have swung sharply higher, buoyed by several factors. Could they be poised to lead the market though the next big upturn?

Other symbols: NBIXCPRXVRTX
2 months ago - Investors Business Daily

BioMarin's Gene Therapy for Adults with Severe Hemophilia A, ROCTAVIAN™ (valoctocogene roxaparvovec), Assessed to Pro...

Institute for Clinical and Economic Review (ICER) Base-Case Model Report Results in $4 Million Savings Versus Emicizumab Prophylaxis Per Patient Over a Lifetime Biologics License Application (BLA) Resub...

2 months ago - PRNewsWire